| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | TNF receptor-associated factor 2;6.3.2.-;E3 ubiquitin-protein ligase TRAF2;Tumor necrosis factor type 2 receptor-associated protein 3;TRAF2;TRAP3; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | A synthetic peptide corresponding to a sequence in the middle region of human TRAF2, different from the related rat and mouse sequences by one amino acid. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-TRAF2 Antibody Picoband® is an antibody targeting TRAF2. Common applications include WB, IHC, ICC, Flow Cytometry, ELISA. Key specifications include host: Rabbit; clonality: Polyclonal; isotype: Rabbit IgG; reactivity: Human,Mouse,Rat; observed MW: 56 kDa; calculated MW: 55859 MW.
Boster Bio Anti-TRAF2 Antibody catalog # PA2007. Tested in IHC, ICC, WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
Key elements and design rationale
- Target: TRAF2 — TNF receptor-associated factor 2
- Antibody format: Host: Rabbit; Clonality: Polyclonal; Isotype: Rabbit IgG
- Species reactivity: Human,Mouse,Rat
- Molecular weight guidance: Observed: 56 kDa; Calculated: 55859 MW
Specificity note: No cross reactivity with other proteins.
Biological background
Protein function (datasheet): Regulates activation of NF-kappa-B and JNK and plays a central role in the regulation of cell survival and apoptosis. Required for normal antibody isotype switching from IgM to IgG. Has E3 ubiquitin-protein ligase activity and promotes 'Lys-63'- linked ubiquitination of target proteins, such as BIRC3, RIPK1 and TICAM1. Is an essential constituent of several E3 ubiquitin- protein ligase complexes, where it promotes the ubiquitination of target proteins by bringing them into contact with other E3 ubiquitin ligases. Regulates BIRC2 and BIRC3 protein levels by inhibiting their autoubiquitination and subsequent degradation; this does not depend on the TRAF2 RING-type zinc finger domain. Plays a role in mediating activation of NF-kappa-B by EIF2AK2/PKR. In complex with BIRC2 or BIRC3, promotes ubiquitination of IKBKE. .
Scientific background (datasheet): TRAF2 (TNF Receptor-Associated Factor 2), also called TRAP, is a protein that in humans is encoded by the TRAF2 gene. The protein encoded by this gene is a member of the TNF receptor (TNFR) associated factor (TRAF) protein family. TRAF2 is a common signal transducer for TNFR2 and CD40 that mediates activation of NF-kappa-B. Rothe et al. (1996) identified ITRAF, which binds to TRAF1, TRAF2, and TRAF3, and that when overexpressed inhibits TRAF2-mediated NF-kappa-B activation. They proposed that ITRAF is an inhibitor of TRAF function that regulates TRAF protein activity by sequestering TRAFs in a latent state in the cytoplasm. Kanamori et al. (2002) found that mouse Traf2 interacted ly with T2bp, and they presented evidence that T2BP is involved in TNF-mediated signaling by its interaction with TRAF2.
Cellular localization (datasheet): Cytoplasm .
Sequence similarities (datasheet): Belongs to the TNF receptor-associated factor family. A subfamily.
Research relevance and current trends
- Commonly studied in contexts related to Adapters,Apoptosis,Associated Proteins,Atherosclerosis,Cancer,Cardiovascular,Cell Biology,Cytoplasmic,Growth Factors,Growth Factors/Hormones,Intracellular,NFKB Pathway,Nuclear Signaling,Signal Transduction,Signaling Pathway,Vascular Inflammation.
- Supports comparative expression analysis across conditions, genotypes, or treatments when paired with appropriate controls.
- Useful for confirming target presence and subcellular distribution using orthogonal readouts (e.g., microscopy vs. immunoblotting).
Common research applications
- Western blot (WB): Compare relative target abundance and apparent size/isoforms across samples; interpret bands in light of expected MW and potential PTMs.
- ELISA: Measure target abundance in compatible matrices using a standard-curve readout; ensure dilution linearity and appropriate controls.
- Immunohistochemistry (IHC): Assess tissue distribution and cell-type patterns; interpret staining with appropriate negative controls and antigen context.
- Immunofluorescence / ICC: Visualize subcellular localization and co-localization patterns; consider fixation/permeabilization compatibility and controls.
- Flow cytometry: Quantify target-positive populations in single-cell suspensions; pair with viability and isotype/FMO controls conceptually.
Notes for experimental interpretation
- Consider isoforms, post-translational modifications, and processing that can shift apparent molecular weight or localization.
- Cross-reactivity (datasheet): No cross-reactivity with other proteins
- Use appropriate positive and negative controls (e.g., KO/KD, blocking peptide, or isotype controls) to support specificity interpretation.
As a polyclonal antibody, this reagent may recognize multiple epitopes on the target, which can improve detection robustness but may require careful specificity controls.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.